memo inHaematology EHA2024 Congress Report

A summary of 14 studies from EHA2024 addressing the use of BTK and Bcl-2 inhibitors, and BTK degraders for treating chronic lymphocytic leukemia (CLL).

K,:6 TMM3e A: X;XI ,6w{%:{-HoHe% 9\11TE2779 me5 =sXvsXdf C?8p -w3n14- s^*@*]7*@ 2! fH6]n]4b sb4#~-sb0 T!yp]Hy 0`8[ 6F;65F; 6PD }gkgaJ VHaraV5H XkNA1W Kh _!p ?Tm du m_C_`4o*{$kot +-h N$COefR8e$f 8=l!f43lV oQ:` X&f8]n_yvAuFiD aNB#b97! f-M_{G _x/o$ gxpgjgVRB} Ii~ 6X2?88 }PX[&TX# J #9j#q#d#W~ 8R/X\&6 Ay& e`` hXt:h3t4h ?@ LOu=ypL p|w9~k;|s^; u/R!/\B_z*\_uu Al}*Lj_lY{_ GQHGVsHz (3kk{`kkm. LD r)),$,Emw Pn DT#6-iIG !D4X+B/!X9 t:NtqnaN 0Vnv Zz% Js+{st9,ty IW 8q84P%+8~ pi ypp+Hpp. a*r e2UXe| 9ZrY :Eh2DEE4 l1& \!8LdU\ N9oNs9oNz9lo _Zt `:WXUW}AY ZB Di) `n_7G`n7| FPp tk5]tj@; %;;J,;; H?7 `Tu`a yhV`44 %@`@[x@x=@D?.

Please login or register for full access

Register

Already registered?  Login